retatrutide parkinson clinical trial Lilly Prepares for FDA Filing Following Additional Phase 3 Data in Diabetes, CVD VisualAbstract: Retatrutide reduces body weight

DHvR has acted as a consultant and received honoraria from Boehringer Ingelheim and Eli Lilly, MSD, Novo Nordisk, and Sanofi and has received research operating funds from Boehringer Ingelheim-Eli Lilly Diabetes Alliance, MSD, AstraZeneca, and Novo Nordisk

While uncommon, some studies suggest NAION may occur slightly more often in people taking GLP-1 medications

It's a GLP-1 thing

Since the use of animal insulin for the treatment of diabetes in 1922, about nine major classes of drugs for the treatment of diabetes have been discovered and developed worldwide, including sulfonylureas, biguanides, -glucosidase inhibitors, insulins, thiazolidinediones (TZDs), meglitinides, GLP-1RAs, DPP-4 inhibitors, and SGLT-2 inhibitors

prescribed off-label for weight loss when appropriate

A proportion of participants in the retatrutide trial discontinued treatment due to gastrointestinal side effects that did not resolve